Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus.

Abstract

AIMS:

To evaluate the long-term effectiveness of Humalog insulin in lowering post meal glucose excursions.

METHODS:

Twenty young subjects with Type 1 diabetes mellitus (DM) who had received insulin-lispro (Humalog) for a least 1 year (mean +/- SD 1.8+/-1.6 years) were studied on two occasions, 3-14 days apart. They consumed a similar breakfast consisting of 450-600 kCal having fasted overnight. The same amount of human soluble Humulin Regular or Humalog insulin was given 10 min before the meal in a randomized, double-blind fashion.

RESULTS:

Postprandial glucose excursions at 30, 60, and 120 min were significantly lower (P<0.001, ANCOVA) when subjects received Humalog as compared to human soluble insulin. Serum-free insulin levels were significantly higher (P<0.001, ANOVA) at 30 and 60 min when subjects received Humalog as compared with human soluble insulin. Humalog antibody levels after up to 5.4 years of receiving Humalog insulin were not elevated beyond the values at 1 year.

CONCLUSIONS:

We conclude that Humalog insulin is effective in lowering postprandial glucose excursions even after up to 5.4 years of treatment.

• Authors: S K Garg, J H Anderson, S V Perry, T Mackenzie, P Keith, M K Jennings, M M Hansen, H P Chase
• Journal: Diabetic medicine : a journal of the British Diabetic Association (Diabet Med) Vol. 16 Issue 5 Pg. 384-7 (May 1999) ISSN: 0742-3071 [Print] England
• PMID: 10342337 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Blood Glucose
• Hypoglycemic Agents
• Insulin
• Insulin Antibodies
• Insulin Lispro

Topics

• Adult
• Blood Glucose (metabolism)
• Cross-Over Studies
• Diabetes Mellitus, Type 1 (blood, drug therapy, immunology)
• Double-Blind Method
• Eating
• Female
• Humans
• Hypoglycemic Agents (immunology, therapeutic use)
• Insulin (analogs & derivatives, immunology, therapeutic use)
• Insulin Antibodies (blood)
• Insulin Lispro
• Male
• Postprandial Period
• Time Factors